title: Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
abstract: In this randomised, double-blind, comparator-controlled, multicentre study conducted in China, 142 hospitalised patients aged 18-75 years with pneumonia (n=80) or complicated skin and soft-tissue infection (cSSTI) (n=62) due to suspected or known Gram-positive pathogens were randomised (1:1) to receive either linezolid 600mg (n=71) or vancomycin 1g in patients aged < or =60 years or 0.75g in patients aged >60 years (n=71) intravenously every 12h. The duration of treatment was 10-21 days for patients with pneumonia and 7-21 days for patients with cSSTI. Clinical outcomes were assessed at end-of-treatment (EOT) visit and follow-up (FU) visit 7-28 days post therapy. Staphylococcus aureus was the most common pathogen at baseline and most of these isolates were resistant to meticillin. All isolates were susceptible to linezolid and vancomycin. For the evaluable patients, the effective treatment rate for linezolid was higher than that for vancomycin at EOT (86.9% (53/61) vs. 61.7% (37/60)) and at FU (83.1% (49/59) vs. 64.9% (37/57)). Pathogen eradication rates for the microbiologically evaluable patients at FU were 79.2% (42/53) for linezolid and 61.5% (32/52) for vancomycin. The incidence of drug-related adverse events (AEs) was 25.4% (18/71) for linezolid and 16.9% (12/71) for vancomycin. Four (5.6%) linezolid-treated and eight (11.3%) vancomycin-treated patients discontinued the study drug because of an AE. Linezolid was well tolerated and effective for the treatment of infections caused by Gram-positive pathogens, including meticillin-resistant S. aureus.
authors.affiliation: Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai 200040, China.
authors.forename: Dong-Fang
authors.initials: DF
authors.lastname: Lin
authors.forename: Ying-Yuan
authors.initials: YY
authors.lastname: Zhang
authors.forename: Ju-Fang
authors.initials: JF
authors.lastname: Wu
authors.forename: Fu
authors.initials: F
authors.lastname: Wang
authors.forename: Jing-Chuan
authors.initials: JC
authors.lastname: Zheng
authors.forename: Jing-Zhi
authors.initials: JZ
authors.lastname: Miao
authors.forename: Li-Ye
authors.initials: LY
authors.lastname: Zheng
authors.forename: Rui-Yuan
authors.initials: RY
authors.lastname: Sheng
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.forename: Hua-Hao
authors.initials: HH
authors.lastname: Shen
authors.forename: Margaret Marian
authors.initials: MM
authors.lastname: Ijzerman
authors.forename: Rodney Victor
authors.initials: RV
authors.lastname: Croos-Dabrera
authors.forename: Wei
authors.initials: W
authors.lastname: Sheng
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002681:China; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D004311:Double-Blind Method; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000382:microbiology; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000382:microbiology; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid